#Canada #Toronto #Wound Care #MolecuLight #fluorescence imaging

Transformative Wound Care through MolecuLight

MolecuLight Inc., a global leader in point-of-care fluorescence imaging for wound treatment, recently announced the results of the largest independent randomized controlled trial (RCT) assessing its technology's impact on wound debridement. Conducted by clinicians at Shuang-Ho Hospital in Taipei, the study has unveiled substantial advancements in patient outcomes and a notable reduction in healthcare costs associated with the use of MolecuLight devices.

The trial, which involved 200 participants, was titled "Application of Perioperative Real-Time Fluorescence Imaging for High-Quality Debridement: A Randomized Control Trial" and is featured in the Advances in Wound Care Journal. The research revealed that incorporating MolecuLight's real-time fluorescence imaging into standard surgical protocols enables a higher quality of debridement, significantly diminishing residual bacterial load. This in turn results in faster wound healing and fewer complications:

• - Faster Healing Times: Patients treated with MolecuLight-guided debridement exhibited an average healing time of 49 days, compared to 63 days for those undergoing standard surgical debridement.
• - Lower Post-Operative Infection Rates: The post-operative infection rate dropped dramatically in the MolecuLight group to just 4%, compared to 22% in the control group, highlighting the method's effectiveness in reducing complications.
• - Shorter Hospital Stays: Patients in the MolecuLight group spent an average of 18 days in the hospital, versus 22 days for their counterparts, leading to enhanced patient throughput in healthcare facilities.
• - Cost Savings on Antibiotics: The duration of antibiotic treatment was considerably shorter among MolecuLight participants, translating to a nearly 40% reduction in antibiotic-related costs.

Dr. Shun-Cheng Chang, a lead author and Associate Professor at the Integrated Burn and Wound Care Center at Shuang-Ho Hospital, expressed, "This RCT demonstrates that MolecuLight offers measurable and clinically significant benefits in wound treatment. The ability to visualize bacterial load in real-time allows surgeons to achieve better quality debridement and faster healing times, while also serving as a vital educational tool for training young physicians in infection control and perioperative assessment of wounds."

Wei-Pin Hsieh, CEO of Healtdeva Company Ltd, MolecuLight's distributor in Taiwan, remarked, "We are honored to provide advanced imaging technology to Taiwanese clinicians. This randomized clinical trial confirms what many practitioners have already witnessed in their practices—that real-time fluorescence imaging enables more precise decision-making, reduces complications, and enhances patient outcomes while alleviating the burden on healthcare systems."

Anil Amlani, CEO of MolecuLight Inc., noted, "This landmark comparative clinical trial provides the highest level of clinical evidence validating MolecuLight's technology. These results not only showcase significant clinical advantages—such as quicker healing, fewer reinfections, and shorter hospital stays—but also the economic value of our imaging system in the management of chronic wounds. We commend the exceptional work of the research team at Shuang-Ho Hospital and take pride in seeing MolecuLight advance global standards of care in wound management and surgical infection control."

The findings of this independent RCT bolster MolecuLight's expanding role in wound care and perioperative surgical applications worldwide. By enabling real-time visualization of bacterial presence, this advanced imaging platform equips clinicians with critical information at the point of care, transforming wound treatment protocols and improving patient outcomes.

About MolecuLight Inc.

MolecuLight Inc. is a private medical imaging company that manufactures and markets the MolecuLight i:X® and DX® wound imaging devices. These are the only Class II imaging devices approved by the FDA for the real-time detection of elevated bacterial load in wounds. They also provide accurate digital measurements of wounds for comprehensive wound management, supported by over 100 peer-reviewed clinical publications.

About Healtdeva Company Ltd.

Founded in 1992 and based in Taipei, Taiwan, Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions. With a well-established network within hospitals, clinics, and retail pharmaceuticals, Healtdeva partners with global innovators to deliver cutting-edge medical solutions to the Taiwanese market, facilitating clinical adoption and commercial success through local expertise and strategic channel integration.